Market Overview - On Thursday, the three major U.S. stock indices showed mixed performance, while the Hang Seng Index ADR rose, closing at 26,429.77 points, an increase of 48.75 points or 0.18% compared to the Hong Kong market close [1]. Company Performance - Major blue-chip stocks exhibited varied performance: HSBC Holdings closed at HKD 147.859, up 1.97% from the Hong Kong market close; Tencent Holdings closed at HKD 513.204, up 0.24% [3]. - Tencent Holdings reported a price of HKD 512.000, with a decline of 2.01%, while its ADR price was 513.204, reflecting a 0.24% increase [4]. - Alibaba Group's stock price was HKD 143.000, down 3.57%, with its ADR at 144.779, showing an increase of 1.779% [4]. - HSBC's stock price was HKD 145.000, up 1.61%, with its ADR at 147.859, reflecting a 1.97% increase [4]. - China Ping An's stock price decreased by 4.64% to HKD 67.850, while its ADR showed a slight increase of 0.49% [4]. - Meituan's stock price fell by 2.72% to HKD 80.450, with its ADR showing a minimal change of -0.03% [4].

Core Viewpoint - BeiGene achieved a significant milestone by reporting its first annual profit in 2025, with total revenue reaching 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit of 1.422 billion yuan, recovering from a net loss of 4.978 billion yuan in the previous year [1][5]. Financial Performance - Total revenue for 2025 was 38.205 billion yuan, up from 27.214 billion yuan in the previous year, marking a 40.4% increase [3]. - Product revenue contributed 37.770 billion yuan, reflecting a 39.9% increase from 26.994 billion yuan [3]. - Operating profit was 2.562 billion yuan, a turnaround from an operating loss of 4.162 billion yuan [3]. - Total profit amounted to 2.558 billion yuan, compared to a loss of 4.163 billion yuan in the prior year [3]. - Net profit attributable to the parent company was 1.422 billion yuan, recovering from a loss of 4.978 billion yuan [3]. Product Performance - The growth in product revenue was primarily driven by the sales of the BTK inhibitor Brukinsa (Zebutinib) and the PD-1 inhibitor Tislelizumab [5]. - Brukinsa achieved global sales of 28.067 billion yuan in 2025, a 48.8% increase year-on-year, making it the first "blockbuster" drug in China's pharmaceutical sector [5][6]. - Sales in the U.S. market for Brukinsa reached 20.206 billion yuan, up 45.5%, while sales in Europe and China were 4.265 billion yuan (66.4% increase) and 2.472 billion yuan (33.1% increase), respectively [6]. Regulatory Approvals and Pipeline - Brukinsa has been approved in over 75 markets globally, with recent updates in the U.S., EU, and UK based on positive results from the Phase 3 ALPINE trial [6][7]. - Tislelizumab has been approved in over 50 markets, with plans to submit new indications for gastric cancer treatment in the U.S. and China in 2026 [7]. R&D and Future Outlook - The company is focusing on diversifying its product pipeline to reduce reliance on Brukinsa, with several candidates in late-stage clinical trials [8]. - BeiGene's product BeiGene (Sotigalimab) has received approval for the first global marketing application in China for certain types of lymphoma [9]. - The company anticipates launching multiple candidates for solid tumors and has received fast-track designation for BGB-B2033 for liver cancer treatment [9][10]. - For 2026, BeiGene projects revenue between 43.6 billion and 45 billion yuan, representing a growth rate of 14.12% to 17.79% compared to 2025 [11].

格隆汇2月26日丨百济神州(688235.SH)公布，预计2026年营业收入将介于人民币436亿元至450亿元之 间，毛利率约为80%区间的高位，营业收入扣除经调整的经营成本费用将介于人民币98亿元至105亿元 之间。 ...

智通财经APP讯，百济神州(688235.SH)发布公告，综合近年来的业务发展趋势，公司预计中国企业会 计准则下2026年营业收入将介于人民币436亿元至450亿元之间，毛利率%80%区间的高位，研发费用、 销售及管理费用合计将介于人民币333亿元至348亿元之间，营业收入扣除营业成本、研发费用、销售及 管理费用、税金及附加("经营成本费用")将介于人民币46亿元至53亿元之间，营业收入扣除经调整的经 营成本费用将介于人民币98亿元至105亿元之间。 ...

Core Viewpoint - The stock price of BeiGene (ONC.NS, 06160.HK, 688235.SH) experienced a significant drop of 9.16% on February 26, leading to concerns about the company's upcoming earnings report, with its market capitalization falling below HKD 300 billion to HKD 299.5 billion [2] Group 1: Financial Performance - For the fiscal year 2025, the company reported total revenue of RMB 38.205 billion, representing a year-on-year growth of 40.4% [2] - The net profit attributable to the parent company reached RMB 1.422 billion, marking the first time the company achieved annual profitability [2] - The highest revenue-generating product, BTK inhibitor Brukinsa (Zebutinib), achieved global sales of RMB 28.067 billion, with a year-on-year growth rate of 48.8%, although this growth rate has slowed compared to the doubling growth seen in 2023 and 2024 [2][3] Group 2: Product Performance - In the U.S. market, which remains the largest commercial market for Brukinsa, sales reached RMB 20.206 billion, growing by 45.5%, but this growth rate is lower than the 107.5% growth rate in 2024 [3] - The second highest revenue product, PD-1 monoclonal antibody Tislelizumab, achieved global sales of RMB 5.297 billion, with a year-on-year increase of 18.6% [3] Group 3: Future Outlook - The company forecasts that for 2026, revenue will be between RMB 43.6 billion and RMB 45 billion, indicating a growth rate of 14.12% to 17.79% compared to 2025 [3] - BeiGene is working to reduce its reliance on Brukinsa by advancing multiple late-stage pipeline products, including the BCL2 inhibitor, which has received the first global marketing authorization application approval in China for certain adult patients [4] - The company has submitted a marketing authorization application for this product in the EU and expects a regulatory decision from the U.S. FDA in the first half of 2026 [4]

2025年，产品收入为377.70亿元，上年同期产品收入为269.94亿元，产品收入的增长主要得益于百悦泽 ®(泽布替尼)，以及安进公司授权产品和百泽安®(替雷利珠单抗)的销售增长。 2025年，百悦泽®全球销 售额总计280.67亿元，同比增长48.8%，已在BTK抑制剂领域稳固确立全球领导者的地位。 报告期内，公司营业收入增加40.4%，主要得益于百悦泽®，以及安进公司授权产品和百泽安®的销售 增长。报告期内，公司营业利润、利润总额、归属于母公司所有者的净利润、归属于母公司所有者的扣 除非经常性损益的净利润和基本每股收益较上年同期相比实现盈利，主要得益于产品收入增长和费用管 理推动的经营效率提升。 智通财经APP讯，百济神州(688235.SH)披露2025年度业绩快报，报告期内，公司营业总收入为382.05亿 元，同比上升40.4%;归属于母公司所有者的净利润14.22亿元，同比扭亏为盈。 ...

Financial Data and Key Metrics Changes - In Q4 2025, product revenue reached $1.5 billion, representing a 32% year-over-year growth [24] - BRUKINSA global revenues totaled $1.1 billion in Q4, growing 38%, with full-year revenues of $3.9 billion, a 49% increase [24] - Gross margin improved to 87% from approximately 84% in the prior year, reflecting favorable product mix and cost efficiencies [26][27] - Operating expenses grew by 12% to $4.2 billion, with income from operations totaling $447 million, showcasing profitability [28] Business Line Data and Key Metrics Changes - BRUKINSA established itself as the leading BTK inhibitor globally, with U.S. sales of $845 million in Q4, driven by a volume growth of approximately 30% [24] - TEVIMBRA reported an 18% increase in revenue, reflecting continued market leadership in China [25] - In-licensed products showed a 9% year-over-year growth, contributing to solid execution across geographies [25] Market Data and Key Metrics Changes - The U.S. remains the largest market, generating $850 million with a year-over-year growth of 38% [25] - China revenue totaled $399 million, an 11% increase compared to Q4 2024, supported by market leadership of TEVIMBRA and BRUKINSA [26] - Europe contributed $174 million, with a 53% year-over-year growth, as BRUKINSA continues its launch trajectory [26] Company Strategy and Development Direction - The company aims to deepen its leadership in CLL and expand across hematological malignancies and solid tumors [37] - Plans to advance one to two cornerstone immunology assets towards registration, indicating a strategic shift towards immunology [37] - The company believes it can move faster and achieve better outcomes across other diseases, leveraging its foundational CLL franchise [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiated value proposition of BRUKINSA, emphasizing its safety profile and long-term efficacy [52] - The company anticipates continued strong demand growth in the U.S. with stable net pricing, projecting 2026 revenue between $6.2 billion and $6.4 billion [30] - Management highlighted the importance of addressing unmet medical needs with new product launches, including sonrotoclax and zanidatamab [30] Other Important Information - The company reported a non-recurring $40 million equity investment impairment in Q4, impacting net income [28] - Free cash flow was over $940 million for the full year 2025, indicating strong cash generation [29] - The company is optimistic about the potential of its new pipeline assets, including a proprietary off-the-shelf iPSC-derived gamma delta T-cell therapy [40] Q&A Session Summary Question: Potential net pricing development in the BTK inhibitor market - Management emphasized BRUKINSA's differentiated value proposition and its best-in-class status, which should mitigate pricing pressures from competitors entering the market [51][52] Question: Guidance assumptions regarding competition from AV or Jaypirca - Management noted that AV's clinical profile does not meet the standards for treatment in CLL, and they remain confident in BRUKINSA's position [56] Question: Strategy for immunology pipeline development - The company aims to identify 1 or 2 cornerstone assets in immunology over the next few years, with a focus on being first or best in class [61][63] Question: Impact of ZS becoming the fixed duration regimen of choice on BRUKINSA revenues - Management explained that the combination of sonrotoclax and zanubrutinib would open up a new market segment, potentially expanding overall market share [68][70] Question: Update on BTK degrader approval timeline - Management confirmed that there has been no change in the timing for the BTK degrader's approval, with plans to interact with the FDA midyear [76]

Financial Data and Key Metrics Changes - In Q4 2025, product revenue reached $1.5 billion, representing a 32% year-over-year growth [24] - BRUKINSA global revenues totaled $1.1 billion in Q4, growing 38%, with full-year revenues of $3.9 billion, reflecting a 49% increase [24][30] - Gross margin improved to 87% from approximately 84% in the prior year, driven by favorable product mix and cost efficiencies [26][27] - Operating expenses grew by 12% to $4.2 billion, while income from operations totaled $447 million, indicating profitability [28] Business Line Data and Key Metrics Changes - BRUKINSA established itself as the leading BTK inhibitor globally, with a significant gap widening against competitors [6] - TEVIMBRA reported an 18% increase in revenue, reflecting continued market leadership in China [25] - In the U.S., BRUKINSA sales in Q4 were $845 million, driven by volume growth of approximately 30% [24] Market Data and Key Metrics Changes - The CLL market is valued at $12 billion and is growing due to therapeutic innovations [7] - China revenue totaled $399 million, an 11% increase compared to Q4 2024, supported by market leadership of TEVIMBRA and BRUKINSA [26] - Europe contributed $174 million, with 53% year-over-year growth, as BRUKINSA continues its launch trajectory [26] Company Strategy and Development Direction - The company aims to deepen its leadership in CLL and expand into hematological malignancies and solid tumors [37] - Plans include advancing one to two cornerstone immunology assets towards registration [37] - The company is focused on developing a more efficacious fixed-duration regimen that addresses unmet needs in the market [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiated value proposition of BRUKINSA, emphasizing its safety and efficacy compared to competitors [52] - The company anticipates continued strong demand growth in the U.S. and stable net pricing, projecting 2026 revenue between $6.2 billion and $6.4 billion [30][31] - Management highlighted the importance of addressing the unmet needs in the CLL market and the potential for BRUKINSA to serve as a foundational therapy [38] Other Important Information - The company achieved significant product revenue growth, GAAP profitability, and meaningful cash flow generation in 2025 [6] - The R&D pipeline saw major advancements, with five assets achieving clinical proof of concept in 2025 [34] - The company is leveraging AI and automation to enhance clinical trial execution and data analysis [46] Q&A Session Summary Question: Can you comment on potential net pricing development in the BTK inhibitor market? - Management highlighted BRUKINSA's differentiated value proposition and its best-in-class status, indicating confidence in maintaining its market position despite competitive pressures [52] Question: What are the assumptions regarding competition from AV or Jaypirca? - Management noted that AV was studied in a limited patient population and expressed confidence in BRUKINSA's clinical profile, suggesting that AV does not meet the necessary treatment criteria [56] Question: Can you elaborate on the strategy for immunology beyond hematology and solid tumors? - Management indicated that approximately 20% of their assets are focused on immunology, with plans to identify one or two cornerstone assets in the next 2-3 years [62] Question: How will the introduction of ZS as a fixed-duration regimen affect BRUKINSA's revenues? - Management explained that the combination of sonrotoclax and zanubrutinib would open up a new market segment, allowing for growth without sacrificing existing revenues from continuous use [68]

Financial Data and Key Metrics Changes - In Q4 2025, product revenue reached $1.5 billion, representing a 32% year-over-year growth [23] - BRUKINSA global revenues totaled $1.1 billion in Q4, growing 38%, with full-year revenues of $3.9 billion, a 49% increase [23] - Gross margin improved to 87% from approximately 84% in the prior year, driven by favorable product mix and cost efficiencies [25] - Operating expenses grew by 12% to $4.2 billion, while income from operations totaled $447 million, indicating profitability [26] - Non-GAAP net income for 2025 was $918 million, translating to diluted non-GAAP earnings per ADS of $8.09 [27] Business Line Data and Key Metrics Changes - BRUKINSA established itself as the leading BTK inhibitor globally, capturing approximately half of the continuous BTK segment of the market [21] - TEVIMBRA reported an 18% increase in revenue, reflecting continued market leadership in China [24] - In the U.S., BRUKINSA sales in Q4 were $845 million, driven by volume growth of approximately 30% [23] - China revenue totaled $399 million, an 11% increase, supported by TEVIMBRA and BRUKINSA's market leadership [25] Market Data and Key Metrics Changes - The CLL market is valued at $12 billion and is growing due to therapeutic innovations [5] - The U.S. remains the largest market for BRUKINSA, generating $850 million with year-over-year growth of 38% [24] - Europe contributed $174 million, with 53% year-over-year growth, as BRUKINSA continues its launch trajectory [25] - Rest of world markets grew 74%, driven by market expansion and new launches [25] Company Strategy and Development Direction - The company aims to deepen its leadership in CLL with three foundational medicines and expand into hematological malignancies and solid tumors [35] - Plans include advancing one to two potential cornerstone immunology assets towards registration [35] - The company is focused on developing a more efficacious, time-limited regimen that addresses unmet needs in the CLL market [19] - The strategy includes leveraging the differentiated clinical data of BRUKINSA to maintain a competitive edge [48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for BRUKINSA and stable net pricing in the U.S. market [28] - The company anticipates revenue growth between $6.2 billion and $6.4 billion for 2026, driven by global expansion and new product launches [29] - Management highlighted the importance of clinical data in establishing BRUKINSA as a best-in-class product [48] Other Important Information - The company initiated three phase 3 studies for its BTK degrader and made significant progress in solid tumors [33] - The company is advancing a proprietary off-the-shelf iPSC-derived gamma delta T-cell therapy, which is designed to overcome limitations of existing therapies [38] - The global clinical development superhighway is a core competitive advantage, enabling faster and more efficient clinical trials [42] Q&A Session Summary Question: Can you comment on potential net pricing development in the BTK inhibitor market? - Management emphasized BRUKINSA's differentiated value proposition and its best-in-class status, which supports its pricing strategy despite competition [47][48] Question: What are the assumptions regarding competition from AV or Jaypirca? - Management expressed confidence in BRUKINSA's clinical profile and its positioning against competitors, noting that AV does not meet the necessary treatment standards [50][52] Question: Can you clarify the strategy for immunology beyond hematology and solid tumors? - Management indicated that about 20% of their assets are focused on immunology, with plans to identify one or two cornerstone assets in the next 2-3 years [57][59] Question: How will ZS impact continuous BRUKINSA revenues if it becomes the fixed duration regimen of choice? - Management explained that the combination of sonrotoclax and zanubrutinib would open up a new market segment, expanding overall market opportunities rather than cannibalizing existing revenues [61][63] Question: What is the status of the BTK degrader and its potential approval timeline? - Management confirmed that there has been no change in the timing for the BTK degrader's approval, with plans to interact with the FDA midyear [70][71]

Core Viewpoint - The Hong Kong pharmaceutical sector experienced a significant adjustment, with innovative drugs and CXO sectors leading the decline, reflecting a valuation restructuring logic during the industry's high-quality development transition [1][2]. Group 1: Market Performance - Over 60% of the 290 stocks in the Hong Kong healthcare sector declined, with 61 stocks falling more than 4% on the day [1]. - Leading stocks such as Deqi Pharmaceuticals, BeiGene, and WuXi AppTec saw declines of 10.44%, 9.16%, and 8.69% respectively [1]. - The Hong Kong pharmaceutical index closed at 2260.95 points, down 2.60%, with a trading volume of 5.589 billion HKD, indicating a strong short-term profit-taking sentiment [1]. Group 2: Policy Impact - The adjustment coincided with a critical phase of policy implementation, including regular drug procurement, upgraded medical insurance fund supervision, and optimization of the national essential drug list [2]. - The revised Drug Administration Law Implementation Regulations will take effect on May 15, 2026, further strengthening the clinical value-oriented drug research and evaluation [2]. - Despite the policy changes, there is optimism about the potential for a diversified payment system in the healthcare industry, driven by policy dividends and the iteration of commercial health insurance products [2]. Group 3: Company Performance and Outlook - The performance window for leading companies is approaching, contributing to market cautiousness, with BeiGene set to release its financial report after the market close on February 26 [2]. - BeiGene reported a net profit of 1.422 billion CNY for the year, marking a turnaround from losses [2]. - Market experts believe that the recent adjustments do not signify a reversal of long-term industry trends but rather a recalibration of valuations in response to policy transitions [3]. Group 4: Investment Sentiment - Recent southbound capital inflows into the pharmaceutical sector have been weaker compared to technology and energy sectors, indicating a shift in capital allocation [3]. - Industry experts suggest that while short-term policies may disrupt profit expectations, they will ultimately benefit the industry's competitive landscape, allowing leading companies to strengthen their positions through R&D and compliance advantages [3]. - The current market pricing logic is shifting from merely valuing pipeline reserves to a comprehensive assessment of R&D capabilities, commercialization abilities, and compliance [3].